RU2018147040A - Способ лечения синдрома прадера-вилли - Google Patents

Способ лечения синдрома прадера-вилли Download PDF

Info

Publication number
RU2018147040A
RU2018147040A RU2018147040A RU2018147040A RU2018147040A RU 2018147040 A RU2018147040 A RU 2018147040A RU 2018147040 A RU2018147040 A RU 2018147040A RU 2018147040 A RU2018147040 A RU 2018147040A RU 2018147040 A RU2018147040 A RU 2018147040A
Authority
RU
Russia
Prior art keywords
agonist
pde4i
receptor agonist
receptor
use according
Prior art date
Application number
RU2018147040A
Other languages
English (en)
Other versions
RU2748294C2 (ru
RU2018147040A3 (ru
Inventor
Лиза Коул БЕРНЕТТ
Дитер ЭГЛИ
Рудольф Л. ЛЕЙБЕЛ
Сара КОТТЕР
Original Assignee
Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк
Лево Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк, Лево Терапьютикс, Инк. filed Critical Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк
Publication of RU2018147040A publication Critical patent/RU2018147040A/ru
Publication of RU2018147040A3 publication Critical patent/RU2018147040A3/ru
Application granted granted Critical
Publication of RU2748294C2 publication Critical patent/RU2748294C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Luminescent Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (15)

1. Применение ингибитора фосфодиэстеразы-4 (PDE4i) при лечении синдрома Прадера-Вилли (СПВ) у нуждающегося в этом субъекта, улучшая, устраняя или предотвращая, таким образом, один или несколько симптомов СПВ.
2. Применение по п. 1, в котором PDE4i повышает у субъекта концентрации или активность циклического аденозинмонофосфата (цАМФ).
3. Применение по п. 2, в котором СПВ характеризуется пониженной экспрессией Nhlh2.
4. Применение по п. 3, в котором пониженная экспрессия Nhlh2 приводит к пониженной экспрессии Pcsk1.
5. Применение по п. 2, в котором повышение концентраций или активности цАМФ повышает экспрессию Pcsk1.
6. Применение по п. 2, в котором PDE4i является селективным PDE4i.
7. Применение по п. 2, в котором PDE4i является неселективным PDE4L
8. Применение по п. 6, причем селективный PDE4i выбирают из группы, состоящей из AN2728, апремиласта, циломиласта, диазепама, ибудиласта, лютеолина, мезембренона, пикламиласта, рофлумиласта, ролипрама, Е6005, GSK356278 и МK0952.
9. Применение по п. 7, в котором неселективный PDE4i выбирают из метилированных ксантинов и их производных, кофеина, аминофиллина, 3-изобутил-1-метилксантина, параксантина, пентоксифиллина, теобромина и теофиллина.
10. Применение по п. 1, причем один или более симптомов включают в себя гиперфагию, пониженную интенсивность метаболизма, ожирение, гипогонадизм, сниженную выработку гормона роста, пониженный мышечный тонус, нарушения сна, нарушения со стороны желудочно-кишечного тракта, пониженную выносливость, пониженную способность к концентрации, ухудшение когнитивной деятельности, поведенческие нарушения, тревожное расстройство, задержку роста, пониженную способность превращения незрелых гормонов в зрелые и активные формы, а также диабет.
11. Применение по п. 1, причем один или несколько дополнительных терапевтических агентов, эффективных для лечения или улучшения одного или более симптомов СПВ, адаптируют для введения субъекту.
12. Применение по п. 10, в котором незрелые гормоны включают в себя один или более из инсулина, грелина, РГГР (рилизинг-гормон гормона роста), альфа-МСГ (эндогенный лиганд рецептора меланокортина 4), окситоцина, орексина, НФГМ, вазопрессина, нейропептида Y, АПБ (агути-подобный белок) и гонадотропина.
13. Применение по п. 11, в котором один или более дополнительных терапевтических агентов, эффективных для лечения или облечения СПВ, включают в себя инсулин, агонист рецептора инсулина, грелин, агонист рецептора грелина, РГГР, агонист рецептора РГГР, альфа-МСГ, агонист рецептора альфа-МСГ, окситоцин, агонист рецептора окситоцина, орексин, агонист рецептора орексина, НФГМ, агонист рецептора НФГМ, вазопрессин, агонист рецептора вазопрессина, нейропептид Y, агонист рецептора нейропептида Y, АПБ, агонист рецептора АПБ, гонадотропин, агонист рецептора гонадотропина или их комбинации.
14. Применение по п. 1, в котором PDE4i является МK0952.
15. Применение по п. 8, в котором PDE4i является МK0952.
RU2018147040A 2016-06-03 2017-06-02 Способ лечения синдрома прадера-вилли RU2748294C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662345133P 2016-06-03 2016-06-03
US62/345,133 2016-06-03
US201662375662P 2016-08-16 2016-08-16
US62/375,662 2016-08-16
PCT/US2017/035655 WO2017210540A1 (en) 2016-06-03 2017-06-02 Methods of treating prader-willi syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021114228A Division RU2021114228A (ru) 2016-06-03 2017-06-02 Способ лечения синдрома прадера-вилли

Publications (3)

Publication Number Publication Date
RU2018147040A true RU2018147040A (ru) 2020-07-09
RU2018147040A3 RU2018147040A3 (ru) 2020-09-30
RU2748294C2 RU2748294C2 (ru) 2021-05-21

Family

ID=60479034

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018147040A RU2748294C2 (ru) 2016-06-03 2017-06-02 Способ лечения синдрома прадера-вилли
RU2021114228A RU2021114228A (ru) 2016-06-03 2017-06-02 Способ лечения синдрома прадера-вилли

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2021114228A RU2021114228A (ru) 2016-06-03 2017-06-02 Способ лечения синдрома прадера-вилли

Country Status (14)

Country Link
US (2) US10842775B2 (ru)
EP (2) EP3478281B1 (ru)
JP (2) JP7044768B2 (ru)
KR (1) KR102478186B1 (ru)
CN (1) CN109562092B (ru)
AU (1) AU2017275652B2 (ru)
BR (1) BR112018075039A2 (ru)
CA (1) CA3026083C (ru)
ES (1) ES2847126T3 (ru)
IL (2) IL294407B1 (ru)
MX (2) MX2018014942A (ru)
RU (2) RU2748294C2 (ru)
WO (1) WO2017210540A1 (ru)
ZA (1) ZA201808607B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10842775B2 (en) * 2016-06-03 2020-11-24 The Trustees Of Columbia University In The City Of New York Methods of treating Prader-Willi syndrome
CA3058639A1 (en) * 2017-03-31 2018-10-04 Epizyme, Inc. Methods of using ehmt2 inhibitors
WO2018195450A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
WO2019161179A1 (en) * 2018-02-15 2019-08-22 Ovid Therapeutics Inc. Methods of treating developmental syndromes with pde10a inhibitors
EP3852723A4 (en) * 2018-09-20 2022-06-29 Levo Therapeutics, Inc. Stable intranasal formulations of carbetocin
CN111264851A (zh) * 2020-03-03 2020-06-12 河南省儿童医院郑州儿童医院 Pws综合征靶向替代保健食品及其制备方法
US20240238237A1 (en) * 2021-05-04 2024-07-18 Virginia Tech Intellectual Properties, Inc. Conjugated linoleic acid supplementation for disease treatment

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035979A2 (en) * 1999-11-13 2001-05-25 Icos Corporation Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
AU2001253886A1 (en) * 2000-04-12 2001-10-30 Repligen Corporation Methylxanthines in the diagnosis and treatment of autistic disorder
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20030181461A1 (en) 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
WO2004096222A1 (en) * 2003-04-30 2004-11-11 Switch Biotech Ag Use of 1-(5-isoquinolinesulfonyl)homopiperazine, its active metabolites, isomers and salts for treating and preventing hypopigmentary disorders
TW200528455A (en) * 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
US20080250516A1 (en) 2004-03-06 2008-10-09 Irm Llc Prohormone Convertase 1 Mutation Associated with Obesity
US20060062859A1 (en) 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes
CN101361754B (zh) 2007-08-09 2013-04-17 李凌松 稀土元素盐或其药物组合物在制备治疗或预防糖尿病和肥胖症药物中的用途
WO2010062681A2 (en) * 2008-10-30 2010-06-03 University Of South Florida Luteolin and diosmin/diosmetin as novel stat3 inhibitors for treating autism
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
JPWO2011083718A1 (ja) 2010-01-05 2013-05-13 学校法人慶應義塾 肺再生促進剤
DK3081568T3 (da) 2011-05-09 2020-02-24 Eip Pharma Llc Sammensætninger og fremgangsmåder til behandling af alzheimers sygdom
US20140364367A1 (en) * 2013-06-08 2014-12-11 Sedogen, Llc Methods of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia using a katp channel opener
EP3096749B1 (en) * 2014-01-24 2019-05-15 Celgene Corporation Methods for the treatment of obesity using apremilast
CN107106500B (zh) 2014-11-14 2021-07-30 伊森舍丽斯有限公司 用于治疗患有普拉德-威利综合征或史密斯-马吉利综合征的受试者的方法
US10842775B2 (en) * 2016-06-03 2020-11-24 The Trustees Of Columbia University In The City Of New York Methods of treating Prader-Willi syndrome

Also Published As

Publication number Publication date
KR20190031209A (ko) 2019-03-25
CN109562092A (zh) 2019-04-02
AU2017275652B2 (en) 2023-02-16
IL263412A (en) 2018-12-31
IL263412B (en) 2022-08-01
JP7044768B2 (ja) 2022-03-30
MX2020009939A (es) 2021-01-15
JP2022058673A (ja) 2022-04-12
IL294407B1 (en) 2024-09-01
KR102478186B1 (ko) 2022-12-15
JP7329634B2 (ja) 2023-08-18
EP3831376A1 (en) 2021-06-09
CA3026083C (en) 2024-04-02
RU2021114228A (ru) 2021-06-01
RU2748294C2 (ru) 2021-05-21
MX2018014942A (es) 2019-04-24
CN109562092B (zh) 2023-08-22
ZA201808607B (en) 2019-08-28
CA3026083A1 (en) 2017-12-07
EP3478281A4 (en) 2020-02-26
AU2017275652A1 (en) 2018-12-20
US10842775B2 (en) 2020-11-24
US11957656B2 (en) 2024-04-16
EP3478281B1 (en) 2020-12-02
EP3478281A1 (en) 2019-05-08
RU2018147040A3 (ru) 2020-09-30
BR112018075039A2 (pt) 2019-05-14
ES2847126T3 (es) 2021-07-30
WO2017210540A1 (en) 2017-12-07
JP2019522045A (ja) 2019-08-08
IL294407A (en) 2022-08-01
US20210113521A1 (en) 2021-04-22
US20190298686A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
RU2018147040A (ru) Способ лечения синдрома прадера-вилли
Benemei et al. TRP channels
Shahid et al. Orexin A in rat rostral ventrolateral medulla is pressor, sympatho‐excitatory, increases barosensitivity and attenuates the somato‐sympathetic reflex
McGuire et al. Serotonin receptor subtypes required for ventilatory long-term facilitation and its enhancement after chronic intermittent hypoxia in awake rats
Albersen et al. The future is today: emerging drugs for the treatment of erectile dysfunction
Zhang et al. Altered expression of TRPV1 and sensitivity to capsaicin in pulmonary myelinated afferents following chronic airway inflammation in the rat
Kemeny et al. Emotions, the neuroendocrine and immune systems, and health
Mutolo et al. Modulation of the cough reflex by antitussive agents within the caudal aspect of the nucleus tractus solitarii in the rabbit
JP2006514630A5 (ru)
Bentzen et al. Central and peripheral GABAA receptor regulation of the heart rate depends on the conscious state of the animal
McDougall et al. Differential cardiovascular responses to stressors in hypertensive and normotensive rats
Sleight Reflex control of the heart
Foote et al. Sensory innervation of the larynx and the search for mucosal mechanoreceptors
Kellett et al. Central 5‐HT7 receptors are critical for reflex activation of cardiac vagal drive in anaesthetized rats
Kim et al. Neural aspects of allergic rhinitis
Uddin et al. Circadian rhythm of onset of stroke-in 50 cases of ischemic stroke.
Harriott et al. Electrophysiological properties of dural afferents in the absence and presence of inflammatory mediators
Kadowaki et al. Central command does not decrease cardiac parasympathetic efferent nerve activity during spontaneous fictive motor activity in decerebrate cats
Dutschmann et al. The potency of different serotonergic agonists in counteracting opioid evoked cardiorespiratory disturbances
NZ597222A (en) Substituted 8-[6-Amino-3-Pyridyl]Xanthines
Touiki et al. Effects of tobacco and cigarette smoke extracts on serotonergic raphe neurons in the rat
Kundrotiene et al. The NMDA NR2B subunit-selective receptor antagonist, CP-101,606, enhances the functional recovery the NMDA NR2B subunit-selective receptor and reduces brain damage after cortical compression-induced brain ischemia.
Lee et al. Activation of presynaptic A1‐receptors by endogenous adenosine inhibits acetylcholine release in the guinea‐pig ileum
Huang et al. Prenatal nicotine exposure alters the types of nicotinic receptors that facilitate excitatory inputs to cardiac vagal neurons
Reynolds et al. Adenosine induces a cholinergic tracheal reflex contraction in guinea pigs in vivo via an adenosine A1 receptor-dependent mechanism